Hajaj E, Eisenberg G, Klein S, Frankenburg S, Merims S, Ben David I, et al. SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. elife. 2020;9: pubmed publisher

Qiu F, Jiang P, Zhang G, An J, Ruan K, Lyu X, et al. Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nat Commun. 2024;15:4327 pubmed publisher

Cheng H, Qiu Y, Xu Y, Chen L, Ma K, Tao M, et al. Extracellular acidosis restricts one-carbon metabolism and preserves T cell stemness. Nat Metab. 2023;5:314-330 pubmed publisher

Ma K, Sun L, Shen M, Zhang X, Xiao Z, Wang J, et al. Functional assessment of the cell-autonomous role of NADase CD38 in regulating CD8+ T cell exhaustion. iScience. 2022;25:104347 pubmed publisher

Ozga A, Chow M, Lopes M, Servis R, Di Pilato M, Dehio P, et al. CXCL10 chemokine regulates heterogeneity of the CD8+ T cell response and viral set point during chronic infection. Immunity. 2022;55:82-97.e8 pubmed publisher

Di Pilato M, Kfuri Rubens R, Pruessmann J, Ozga A, Messemaker M, Cadilha B, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;: pubmed publisher

Mitchell J, Lund M, Starmer J, Ge K, Magnuson T, Shpargel K, et al. UTX promotes CD8+ T cell-mediated antiviral defenses but reduces T cell durability. Cell Rep. 2021;35:108966 pubmed publisher

Cervera Carrascon V, Quixabeira D, Santos J, Havunen R, Zafar S, Hemminki O, et al. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. Oncoimmunology. 2020;9:1761229 pubmed publisher

Fu G, Chen X, Hu H, Yang H, Xu X, Qiu T, et al. Emergence of peripheral CD3+CD56+ cytokine-induced killer cell in HIV-1-infected Chinese children. Int Immunol. 2012;24:197-206 pubmed publisher